|
Jan 12
|
Insider Sell: EVP, Chief Commercial Officer Benjamin Hickey Sells Shares of Mirati Therapeutics Inc
|
|
Jan 11
|
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
|
|
Jan 10
|
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
|
|
Dec 20
|
Mirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 Shares
|
|
Aug 29
|
Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
|
|
Aug 23
|
Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer
|
|
Aug 21
|
Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer
|
|
Aug 19
|
3 Under-the-Radar Biotech Stocks to Buy in 2023
|
|
Aug 16
|
BOXER CAPITAL, LLC Boosts Stake in Mirati Therapeutics Inc
|
|
Jul 21
|
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
|